| CAS ID: | 216101-59-6 |
| Molecular Formula: | |
| Molecular Weight: | g/mol |
| Monoisotopic Mass: | g/mol |
| Class: | Protein based biotech |
| Natural Product: | No |
| Other Names: | VIOKASE | ENTOLASE | COTAZYM | PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) | PANCREASE | ACCELERASE | PANCRELIPASE | CREON | ILOZYME | LIPANCREATIN | KU-ZYME HP | COTAZYM-S | ZYMASE |
| Analysis: | N/A |
Reference Record 1
| PubMed ID | 19815466 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Cystic fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00510484 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 2, 2007 | Last Verified | June 3, 2010 |
| Sponsor | Solvay Pharmaceuticals | ||
Trial Record 2
| ClinicalTrial ID | NCT02137382 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 13, 2014 | Last Verified | January 22, 2016 |
| Sponsor | Abbott | ||
Trial Record 3
| ClinicalTrial ID | NCT00775528 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 20, 2008 | Last Verified | November 8, 2010 |
| Sponsor | Solvay Pharmaceuticals | ||
Trial Record 4
| ClinicalTrial ID | NCT00690820 | Disease | Cystic fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | June 5, 2008 | Last Verified | June 2, 2010 |
| Sponsor | Solvay Pharmaceuticals | ||
Trial Record 5
| ClinicalTrial ID | NCT01652157 | Disease | Cystic fibrosis |
| Phase | Status | Recruiting | |
| First Received | July 27, 2012 | Last Verified | December 19, 2018 |
| Sponsor | AbbVie (prior sponsor, Abbott) | ||
Trial Record 6
| ClinicalTrial ID | NCT02415959 | Disease | Cystic fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | April 14, 2015 | Last Verified | April 4, 2016 |
| Sponsor | Abbott | ||
| PubChem: | |
| ChEMBL: | CHEMBL2108074 |